Skip to main content

Security report for angelinipharma.es

Angelini Pharma · Healthcare · Spain

Low risk. 4 critical or high findings in GDPR outside view, Email security and 1 other check.

Security score

78/100

Risk levelLow

0–100, higher is better. How it is calculated

Angelini Pharma España is a large, international healthcare company specializing in pharmaceutical products with a strong focus on mental health, central nervous system disorders, pain management, rare diseases, and consumer healthcare products. The company operates as a subsidiary of Angelini S.p.a. and maintains a significant presence across multiple European countries and the USA. Their website reflects a professional and consistent brand image, targeting healthcare professionals and consumers interested in health solutions. The site offers comprehensive information about their therapeutic areas, pipeline, partnerships, and corporate responsibility initiatives. Technically, the website employs modern JavaScript libraries such as jQuery, Slick Carousel, and Magnific Popup, alongside Piwik PRO for analytics and cookie consent management. The site is mobile-optimized with good SEO and accessibility features, although some accessibility and security headers could be improved. Hosting details are not explicitly disclosed but the infrastructure appears stable and performant. From a security perspective, the site uses HTTPS with good SSL configuration and implements cookie consent mechanisms aligned with GDPR requirements. However, explicit security policies, incident response contacts, and vulnerability disclosure mechanisms are not present, which could be areas for enhancement. No critical vulnerabilities or suspicious patterns were detected in the content or WHOIS data. Overall, Angelini Pharma España presents a trustworthy, professional, and compliant digital presence suitable for its industry and audience. Strategic improvements in security headers and transparency policies would further strengthen its security posture and user trust.

Scanned

NIS2 and GDPR posture

GDPR outside view
68/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

4 findings rated critical or high. Fix these first.

  1. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  2. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • High

      No SPF record found

      SPF helps prevent email spoofing

      What to do: Add SPF record: "v=spf1 include:_spf.yourmailprovider.com ~all"

    • High

      No DMARC record found

      DMARC provides email authentication and reporting

      What to do: Add DMARC record: "v=DMARC1; p=none; rua=mailto:dmarc@yourdomain.com"

  3. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching angelinipharma.es

This scan found 14 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
82
Security headers
90
Email security
45
DNS health
85
Network security
100
GDPR outside view
68
Average
78

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Angelini Pharma holds a strong market position as an international leader in healthcare, particularly in mental health and consumer health sectors. Their business model revolves around pharmaceutical manufacturing, research and development, and distribution of prescription and OTC products. The company targets healthcare professionals, patients, and consumers, leveraging a broad portfolio of brands and therapeutic areas. Their extensive partnership network and multiple country-specific subsidiaries indicate a well-established and diversified operational footprint. The presence of certifications like Top Employer Spain and Europe 2025 further supports their credibility and commitment to quality. The website content and structure reflect a mature organization with clear strategic focus and growth potential.

Security posture

The website demonstrates a mature security posture with enforced HTTPS, cookie consent management, and anonymized analytics tracking. However, the absence of explicit security policies, incident response contacts, and vulnerability disclosure mechanisms indicates room for improvement in transparency and preparedness. Security headers such as Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options are not explicitly detected, which are recommended best practices to mitigate common web vulnerabilities. No exposed sensitive data or vulnerable libraries were found. Overall, the security posture is good but could be enhanced by adopting additional security headers and publishing formal security policies.

Recommendations

  1. Implement and enforce Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options HTTP headers to improve protection against common web attacks.
  2. Publish a dedicated security policy page outlining security practices and incident response procedures.
  3. Provide clear incident response contact channels such as security@ or abuse@ email addresses.
  4. Consider adding a vulnerability disclosure policy or security.txt file to encourage responsible reporting of security issues.
  5. Enhance accessibility features to meet higher standards and improve user experience for all visitors.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Angelini Pharma
Description
Grupo internacional líder en atención sanitaria, con especial fuerza y experiencia en el área de la Salud Mental, así como en medicamentos OTC. Angelini Pharma se compromete a identificar soluciones de salud con un enfoque predominante en las áreas del Sistema Nervioso Central (SNC), incluido el dolor y las Enfermedades Raras. La Compañía también es líder en el sector Consumer Health.
Key services
Medicamentos de Prescripción Médica, Productos de Autocuidado (Consumer Healthcare), Investigación y Desarrollo, Producción farmacéutica
Content quality
good
Branding
consistent

Technology

Stack
jQuery 3.7.1, jQuery Validation, Slick Carousel, Magnific Popup, Piwik PRO Analytics, Flip.js
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent mechanism implemented
  • No exposed sensitive data in HTML
  • Use of analytics with anonymization options

Analytics and tracking

Services
Piwik PRO
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Piwik PRO
Marketing tools
Piwik PRO
Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenges.
  2. Strong presence of healthcare-related content and services.
  3. Comprehensive cookie and privacy policies with consent mechanisms.
  4. Clear contact information with company email and phone number.
  5. Use of modern JavaScript libraries and analytics tools.
  6. Good branding consistency and professional design.
  7. No visible security policy or incident response contact found.
  8. No vulnerability disclosure or security.txt detected.
  9. Multiple international subsidiary domains linked.
  10. Social media presence on Twitter, LinkedIn, Instagram, and YouTube.
Technical notes

Notes

The website uses a modern and stable technology stack including jQuery 3.7.1, Slick Carousel for sliders, Magnific Popup for modals, and Flip.js for UI effects. Analytics are handled via Piwik PRO with cookie consent integration, supporting GDPR compliance. The site is mobile-optimized and has good SEO metadata including Open Graph and Twitter Card tags. No major technical debt or deprecated technologies were detected. Performance is moderate, with some room for optimization in loading times and accessibility. The CMS appears custom or proprietary, with no common CMS signatures detected. Hosting provider details are not explicit but the site is reliably served over HTTPS with valid SSL certificates.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with angelinipharma.es. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review angelinipharma.es.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.